Trials, approvals, deal flow, and the long road from preclinical to pharmacy.
Clinical pipelines, drug approvals, and biotech deals.
AI-verified biotech and pharmaceutical intelligence with full provenance.
The biotech startup is developing a differentiated therapy for thyroid eye disease and potentially a related autoimmune condition.
French pharma Servier is buying an experimental tablet for muscular dystrophy from Edgewise Therapeutics, with a deal valued at up to $2.7 billion including milestones.
Interim Phase I data support continued development of a combined vaccine targeting Lassa fever and rabies.
University of Amsterdam researchers show that self-propelled objects, like worms or bacteria, can fundamentally alter the nematic phase transition, a key ordering process in soft matter.
The FDA approved Sanofi's teplizumab (Tzield) for children with stage 3 diabetes, a decision that follows a clash between career staff and the CDER political appointee.
Washington University researchers develop a rapid method to produce and screen disaggregase enzymes that break down misfolded proteins linked to neurodegenerative diseases.
Researchers have named a newly described amphicyonid Paludocyon moyasolai, a medium-sized carnivore from roughly 15.9 million years ago, after a leading Spanish paleontologist.
A new poster presentation highlights Spravato's remission rates in treatment-resistant depression, bolstering Johnson & Johnson's commercial strategy.
The biotech startup raised $125 million to advance its ultrasound-mediated delivery system for genetic medicines, including gene editing and RNA therapeutics.
Researchers at The University of Texas Medical Branch report that a single-dose mRNA vaccine provided complete protection against Andes hantavirus in Syrian hamsters, signaling a potential rapid-response tool for outbreaks.
Abe Ceesay outlines Rapport's strategy to become a commercial-stage brain drugmaker without a partner.
Researchers engineer a microbe that produces high-value bioplastic from raw potato starch in 24 hours, offering a pathway to replace petrochemical plastics.
A series of Lancet publications highlight major therapeutic advances, including atrasentan and finerenone, alongside a new WHO resolution to integrate kidney care globally.
Nonprofit Blood Cancer United acquires a cancer drug, while Lilly and Nvidia invest in Abridge, as Prometheus secures massive capital for artificial engineers.
The genomics pioneer who challenged the Human Genome Project and built the first synthetic cell has died of cancer.
A correction notice has been issued for two figures in a landmark Lancet meta-analysis on ovarian ablation for breast cancer.
New research reveals how cells began sticking together, offering clues to the origins of animal life billions of years ago.
A laser-driven phase contrast method installed in a custom Titan Krios enhances cryo-EM resolution, improving small-protein structural analysis.
Tirzepatide, a dual GLP-1 and GIP receptor agonist, shows superior efficacy over semaglutide in improving HbA1c and weight in type 2 diabetes, raising questions about whether targeting more receptors delivers better outcomes.
A new artificial intelligence model can predict molecular evolution dramatically faster, potentially revolutionizing drug discovery and development.
Five lupus patients in England are in remission after receiving genetically modified T-cell therapy in a pioneering NHS trial, offering hope of a cure for the chronic autoimmune disease.
A new analysis of over 123,000 participants from 19 trials found no causal evidence linking statins to most adverse effects listed on product labels.
Boehringer Ingelheim is advancing survodutide, a GLP-1/glucagon receptor dual agonist, into metabolic dysfunction-associated steatohepatitis (MASH) through its LIVERAGE program.
A review in Nature Reviews Genetics synthesizes evolutionary biology, genomics, and human genetics to explain why modern longevity reveals the late-life effects of natural selection's youth-focused optimization.
Blood Cancer United acquires remaining supplies of an experimental cancer drug to ensure continued access for patients after development was halted.
A deep dive into the evolving obesity drug landscape reveals new contenders, a record-breaking IPO, and looming FDA decisions.
A handbag made from Tyrannosaurus rex cells went unsold at a Paris auction, with bids falling short of expectations.
Researchers at the University of São Paulo have identified 45 previously unknown toxins produced by Salmonella bacteria, offering potential pathways for new antibiotics.
A genome-wide association study in rats identifies genetic markers linked to compulsive cocaine use and a potential therapeutic target in the liver.
Engineered extracellular vesicles delivering full-length DMD mRNA restore dystrophin and improve muscle strength in Duchenne muscular dystrophy models with no notable toxicity.
The developer of a leading PD-1/VEGF cancer drug cited market conditions for canceling a $500 million share offering a day after announcing it.
The RNA drug, acquired through Novartis' $12 billion Avidity deal, shows promise in treating a muscle-wasting disease.
The biotech firm will discontinue its lead gene therapy program for OTOF-related deafness following a strategic review citing a changed competitive landscape.
A STAT News roundup reports increasing prescription drug costs for seniors and updates on Enliven's leukemia treatments, among other biotech developments.
Proving out synthetic lethality for cancer treatment could trigger a wave of mergers and acquisitions in biotech.
Takeda's oral TYK2 inhibitor zasocitinib outperformed Bristol Myers Squibb's Sotyktu in a head-to-head phase 3 trial for moderate-to-severe plaque psoriasis.
Researchers have identified declining phosphatidylcholine levels as a driver of age-related mitochondrial dysfunction, with early evidence that restoration can reverse some aging effects.
Researchers from two Spanish universities have created a floating buoy designed to prevent jellyfish from reaching beaches, reducing sting risks for swimmers.
Researchers have developed an algorithm that maps cellular communication across tissue and time, revealing who is talking to whom.
New research identifies immune and structural changes that may predict brain aneurysm rupture risk, potentially aiding stroke prevention.
New research shows wheat roots release compounds that inhibit soil microbes, reducing nitrogen emissions and improving fertilizer efficiency.
New research challenges the single-encounter theory, suggesting a gradual evolution driven by interactions among multiple bacteria and giant viruses.
GlaxoSmithKline will acquire Nuvalent for $10.6 billion, gaining two late-stage experimental treatments for non-small cell lung cancer.
AI-driven in silico experiments could enhance drug manufacturability and yields, according to a debate at a recent conference.
A new nucleic acid amplification technique offers improved species breadth and sensitivity for Mycoplasma detection in biologics, supporting in-process and release testing.
A gorilla adenovirus originally designed for vaccines demonstrates natural cancer-fighting properties, potentially offering a new therapeutic approach.
A new analysis highlights the persistent challenges U.S. biotech firms face in securing patient capital and achieving rapid exits, even in favorable market conditions.
The drug startup's stock sale is the largest ever for a venture-backed biotech company, extending a 2026 streak of large IPOs.
A new report from Genetic Engineering News outlines the evolving scientific and regulatory landscape facing biologics testing as the industry adapts to 2026 realities.
A new study reveals that highly conserved mRNA tails, known as 3' UTRs, play a key role in facilitating the folding of intrinsically disordered proteins.
Scientists release the full wiring diagram of an adult fruit fly's central nervous system, revealing that complex behaviors arise from distributed local circuits.
Medical students in the UK uncovered an extremely rare case of triphallia—a man with three penises—while dissecting a donated body.
New research reveals how the PTPN22–PSTPIP1 signaling pathway limits T-cell synapse remodeling, offering potential insights for autoimmune disease and cancer immunotherapy.
The trio aims to shift ADME profiling from lead optimization to earlier hit identification using AI and automation.
A new AI model overcomes key limitations in fluorescence image restoration, enhancing speed and fidelity under noisy conditions.
Nature published corrections for studies on genetic compensation and gammaherpesvirus antibodies.
Incyte will acquire Vega Therapeutics for up to $2 billion, gaining a Phase III candidate for von Willebrand disease.
VIVEbiotech has incorporated its fifteenth in vivo lentiviral vector-based therapeutic technology, signaling growing industry investment in in vivo cell and gene therapies.
Researchers identify a population of CD8+ T regulatory cells guided by GPR15 that reduces intestinal inflammation.
Correspondence in The Lancet scrutinizes the EMPHASIS trial's design, noting limitations in statistical robustness and patient selection.
The British drugmaker's third acquisition of the year adds two experimental lung cancer therapies under FDA review.
The stealthy startup, led by former Loxo Oncology CEO Josh Bilenker, has a trio of early-stage cancer drugs and is pursuing a public listing via a reverse merger.
Two major clinical trials published in The Lancet report new findings on tirzepatide for long-term obesity management and dapirolizumab pegol for systemic lupus erythematosus.
Cellular phase separation organizes kinases into condensates that activate growth signals, suggesting a novel therapeutic target.
A new radiopharmaceutical has shown encouraging results in patients who previously received Pluvicto, a leading prostate cancer treatment.
The collaboration will focus on developing next-generation AAV gene therapy candidates for an unspecified muscle disease and in vivo cell therapy.
The funding aims to accelerate development of a vaccine targeting the Bundibugyo strain amid a worsening Ebola outbreak.
Researchers find coordinated neural patterns in zebrafish brains seconds before social behavior begins, with the pallium region playing a key role.
New research finds that created grassland habitats can effectively compensate for nature lost to development, helping bees and hoverflies.
A European research team is developing bacteria that convert sustainable methanol into chemical base materials, aiming to replace fossil resources in everyday products.
HKUMed researchers develop RNA Segment Editing (RSE), a novel tool that precisely removes or replaces faulty RNA segments in living cells.
A coalition of over 100 researchers from six Asian countries has unveiled a coordinated plan to create artificial single-celled biological systems from non-living molecules.
Researchers have mapped eight distinct metabolic niches that reveal how trillions of ocean microbes process carbon, offering new insights into the climate-regulating marine carbon cycle.
The field of targeted protein degradation is evolving with new tools for target validation and translational predictions.
A global coalition is accelerating development of three vaccines against the Ebola strain spreading in Congo, backed by $62 million in new funding.
A new programmable blood test allows scientists to monitor gene activity in the living brain without surgery.
A new neural probe combines electrophysiology and optogenetics to simultaneously record and control brain activity, offering a powerful tool for studying neural circuits.
KAIST researchers develop a sustainable method to produce key nylon building blocks using microorganisms.
Mid-cap buyers, a better capital raising climate, and manufacturing reshoring are shaping U.S. biopharma cluster growth, according to Genetic Engineering News.
Researchers have developed an affordable method to produce large quantities of uniform hydrogel capsules for 3D cell culture, democratizing access to advanced tissue-mimetic studies.
First-patient dosing in Crystalys Therapeutics' AMETHYST trial for dotinurad follows competitor Sobi's positive Phase III results for pozdeutinurad.
At the year's largest cancer conference, head-to-head data between bispecific antibodies and antibody-drug conjugates took center stage, alongside advances in targeting the challenging RAS pathway.
Rare disease company RallyBio announces a plan to merge with Avenzo Therapeutics after its prior deal with Candid Therapeutics fell through.
Using duckweed as an alternative to mammalian expression systems can help manufacturers navigate the patent cliff and shift from blockbusters to biosimilars.
A novel screening approach enables large-scale identification of membrane-permeable synthetic cyclic peptides, advancing a drug modality that blends biologic properties with oral bioavailability.
Industry experts argue artificial intelligence can accelerate clinical trials but cannot fix fundamental flaws in trial design or replace human oversight.
Researchers are preparing to test an oral antiviral for Ebola prevention in exposed individuals, a potential game-changer in outbreak control.
An industry expert argues that recombinant technologies offer a more reliable path for diagnostic test availability, citing concerns over traditional source dependence.
A shift in drug development combines in vivo models with novel methodologies to improve clinical relevance.
Macrocycles, de novo antibodies, and mRNA-based approaches are expanding the drug discovery toolkit for previously intractable targets.
Italian researchers led by Luigi Naldini have developed a new platform to make gene editing in hematopoietic stem cells more precise and safer.
Next-generation mass spectrometry and multiomics workflows accelerate biomarker discovery and therapeutic design.
Detailed study data confirms overall survival improvement for pancreatic cancer patients, marking a significant advance at ASCO.
Corning is helping researchers standardize, scale, and automate organoid science as FDA support for non-animal methods accelerates.
A new opinion piece and podcast discussion highlight the ethical and practical challenges for hospitals when patients demand blood from unvaccinated donors.
A compound originally dubbed 'substance God help me' by its creator finds renewed interest as federal health policy shifts.
Advances in throughput have shifted the critical challenge in spatial atlasing to achieving sufficient sensitivity to detect low-abundance cell populations.
Researchers used AI to analyze CT scans and discovered that a healthier thymus, an often-overlooked organ, correlates with longer life and reduced risks of heart disease and cancer.
New research highlights the use of human brain organoids to evaluate anti-inflammatory therapies for CNS disorders, addressing a gap in clinical success.
A new report highlights the commercial durability and strategic relevance of orphan drugs, supported by a strong development pipeline for 2026.